[{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT\u2011240","moa":"AOPE","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Annogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Annogen","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Annogen"},{"orgOrder":0,"company":"Intravacc","sponsor":"European Union","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Polyglycine alanine","graph1":"Neurology","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intravacc \/ European Union","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ European Union"},{"orgOrder":0,"company":"VectorY","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Forbion"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AAV-VecTabs","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMT-210","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Uniqure \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The collaboration aims to support VectorY’s lead program, VTx-002, which is being evaluated in the early-stage clinical trial studies for the treatment of ALS.

                          Product Name : VTx-002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 18, 2024

                          Lead Product(s) : VTx-002

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : University Medical Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : VTx-002, a vectorized antibody that selectively clears misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells, is being developed for the treatment of Amyotrophic Lateral Sclerosis.

                          Product Name : VTx-002

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 17, 2024

                          Lead Product(s) : VTx-002

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : UMC Utrecht

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Through the proceeds, Kynexis will advance its lead therapeutic candidate, KYN-5356, a potential first-in-class KAT-II inhibitor for the treatment of cognitive impairment associated with schizophrenia (CIAS), toward clinical development.

                          Product Name : KYN-5356

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 11, 2023

                          Lead Product(s) : KYN-5356

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Forbion

                          Deal Size : $62.1 million

                          Deal Type : Series A Financing

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AMT-240 is a one-time-administered gene therapy using uniQure’s miQURE gene-silencing technology to silence the toxic APOE variant, in combination with overexpressing a protective APOE variant as treatment for autosomal dominant Alzheimer’s disease p...

                          Product Name : AMT‑240

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 10, 2022

                          Lead Product(s) : AMT‑240

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules. In a mouse model, this reduces poly-GA aggregates and largely prevents motor deficits.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 07, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : European Union

                          Deal Size : $2.5 million

                          Deal Type : Funding

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : VTx-002, reduce TDP-43 pathological aggregates for treating ALS, TAR-DNA binding protein-43 is necessary for correct processing and transport of multiple mRNA’s that are essential for neuronal survival.

                          Product Name : VTx-002

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 18, 2022

                          Lead Product(s) : VTx-002

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The new data demonstrate therapeutic potential and versatility of VectorY’s VecTab platform technology, enabling development of secreted or intracellular antibody fragments that are AAV-VecTabs delivered to neurons and/or astrocytes, in vitro and in vi...

                          Product Name : AAV-VecTabs

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 06, 2022

                          Lead Product(s) : AAV-VecTabs

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : AMT-210 (miRNA-based AAV Gene Therapy) is a one-time, brain-targeting AAV gene therapy incorporating miQURE gene silencing technology, designed to halt misfolded alpha-synuclein and subsequent fibril formation in familial and sporadic Parkinson’s disea...

                          Product Name : AMT-210

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 05, 2022

                          Lead Product(s) : AMT-210

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          June 15, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Forbion

                          Deal Size : $36.7 million

                          Deal Type : Financing

                          blank